tbuckley/cabot-search huggingface dataset:
PTU-124 The Association of the Joint Hypermobility Syndrome with Functional Gastrointestinal Disorders – an Interesting New finding that may Explain Aetiology
Authors: A Fikree, R Aktar, K V Gillespie, L E Glasgow, J K Morris, A Farmer, R Grahame, C H Knowles, Q Aziz
Journal: Gut (2013)

<h3>Introduction</h3> Functional Gastrointestinal Disorders (FGID) are common, but their cause is unknown. Joint hypermobility syndrome (JHS) is a common non-inflammatory connective tissue disorder characterised by joint hyperflexibility. It is associated with gastrointestinal (GI) symptoms (1), in particular unexplained symptoms (2). The association between JHS and FGID has never been studied. <h3>Methods</h3> A nested case control study in patients aged 18–70 attending secondary care was performed. 694 consecutive new referrals to GI clinics were assessed for JHS using the Brighton criteria, prior to their outpatient consultation. Subsequent investigation by their gastroenterologist led to a diagnosis that was functional, organic or gastrooesophageal reflux (GOR); the latter were excluded due to the mixed aetiology of reflux. The control group consisted of 92 patients referred to secondary care for non-GI symptoms-those with diabetes, pregnancy, neuromuscular disorders or inflammatory arthritis were excluded. Controls were similarly assessed for JHS. JHS prevalence was compared in patients with FGID, organic GI disorders, and controls. <h3>Results</h3> Of the 694 GI patients, 26 had GOR and 52 had not received a diagnosis–these were excluded. Thus 616 GI patients were included in the study: 363 had FGID, 253 had organic disorders. There were no significant age or gender differences between FGID and controls (age: 40.3 ± 0.69 vs 42.7 ± 1.5; 64% vs 67% females). Compared to FGID patients, organic patients were older (43.9 ± 0.92 vs 40.3 ± 0.69, p:0.002) and less likely to be female (54% vs 64%, p:0.008).The prevalence of JHS in FGID patients in secondary care was 40.5%. This was significantly higher than in organic GI patients (26.9%, p:0.000) and in controls (25%, p:0.006). Even after adjusting for age and gender differences, JHS was significantly associated with FGID (p:0.005). <h3>Conclusion</h3> This is the first study that demonstrates a strong association between JHS and FGID, as compared to both organic GI and non-GI conditions. This suggests a potential connective tissue aetiology for 40% of FGID patients in secondary care. Furthermore, the high prevalence of JHS in FGID suggests that this common diagnosis is often overlooked. Our results have implications for future FGID research and efforts must now be focused to determine the mechanism of symptoms and identification of appropriate treatments for this subgroup of patients. <h3>Disclosure of Interest</h3> None Declared <h3>References</h3> Castori, M., <i>et al.</i>, Am J Med Genet A, 2010. <b>152A</b>(3): p. 556–64. Zarate, N., <i>et al.</i>, Neurogastroenterol Motil, 2010. <b>22</b>(3):252-e78.
Abstract 1275: Quantitative proteomic analysis of tumor growth associated proteins in cutaneous malignant melanoma
Authors: Satoshi Serada, Yorihisa Kotobuki, Atsushi Tanemura, Ichiro Katayama, Tetsuji Naka
Journal: Cancer Research (2012)

Abstract BACKGROUND: The identification of proteins responsible for tumor development and regulation is of great value. In this study, we aimed to identify novel functional proteins associated with tumor progression in malignant melanoma. MATERIAL AND METHODS: The proteins extracted from malignant melanoma and normal skin tissue were labeled with iTRAQ reagent and performed a quantitative mass spectrometric analysis using nano LC-MS/MS system. The detected protein expression and localization in cutaneous malignant melanoma tissue was confirmed by immunohistochemistry. Human melanoma cell line (Mewo) was subcutaneously injected into Rag2-/- mice and POSTN-/-Rag2-/-mice, thereafter implanted tumor growth was compared. RESULTS: Among 1314 identified proteins, 118 proteins were increased more than 5.0-fold and 37 proteins were decreased &amp;lt;0.5-fold in malignant melanoma compared to normal tissue. In these proteins, we found significant upregulation of an extracellular matrix protein, periostin (POSTN). POSTN expression was robustly induced in fibroblast cultured with Mewo and evident on the stroma of advanced melanoma tissue, suggesting the importance of interaction of these cells. As an assessment of functional implication in POSTN in malignant melanoma, we observed significant increase in melanoma cell number in the treatment with recombinant POSTN. Moreover, tumor growth in POSTN-/-Rag2-/- mice was significantly suppressed compared with that in Rag2-/- mice.CONCLUSIONS: We newly identified upregulation of POSTN expression in malignant melanoma tissue. POSTN was induced in the co-culture of fibroblast with melanoma cell and showed the growth promoting effect. These results indicate that periostin might be a potential therapeutic target in malignant melanoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1275. doi:1538-7445.AM2012-1275
Coil migration into the common bile duct after embolization of a hepatic artery pseudoaneurysm
Authors: W. Kao, Y. Chiou, T. Chen
Journal: Endoscopy (2011)

A 65-year-old woman was referred to our hospital for thoracic spine metastasis. She had undergone embolization 8 years ago for hemobilia caused by a pseudoaneurysm in the right hepatic artery, which had developed after cholecystectomy with T-tube choledochostomy. Laboratory studies revealed alanine aminotransferase 510 IU/L, total/direct bilirubin 3.69/3.22 mg/dL, alkaline phosphatase 496 U/L, and γ-glutamyltransferase 704 U/L. Abdominal computed tomography showed a high-density coil at the hepatic hilum, compatible with pseudoaneurysm after coil embolization, and marked dilatation of the bilateral intrahepatic bile ducts ([Fig. 1]).
Pyloric gland adenoma arising in gastric heterotopia within the duodenal bulb
Authors: E. Poeschl, F. Siebert, M. Vieth, C. Langner
Journal: Endoscopy (2011)

Pyloric gland adenoma is a peculiar tumor which mainly occurs within the stomach. Rarely, the tumor has been documented to originate from the duodenum and from other extragastric sites [1] [2] [3] [4].
Coached practice using ERCP mechanical simulator improves trainees' ERCP performance: a randomized controlled trial
Authors: Wei-Chih Liao, Joseph Leung, Hsiu-Po Wang, Wen-Hsinug Chang, Cheng-Hsin Chu, Jaw-Town Lin, Robert Wilson, Brian Lim, Felix Leung
Journal: Endoscopy (2013)

Preliminary data suggested that simulation practice using an endoscopic retrograde cholangiopancreatography (ERCP) mechanical simulator (EMS) improved trainees' skill. The aims of the current study were to confirm the impact of coached EMS practice at the beginning of ERCP training and to investigate whether subsequent uncoached EMS practice provides additional benefit.Trainees entering ERCP training in 2008 (n = 8) and 2009 (n = 8) at two referral medical centers were randomized to receive a coached EMS practice either with (2009) or without (2008) subsequent uncoached practices or only routine training (controls). The outcome measures were successful deep biliary cannulation by the trainee and overall performance score as rated by blinded trainers, during the subsequent 3 months of clinical practice.Trainees undergoing single and multiple EMS practices were more likely than controls to achieve successful biliary cannulation (single: adjusted odds ratio [aOR] 2.89, 95 % confidence interval [CI] 2.21 - 3.80 [P < 0.001]; multiple: 3.09, 95 %CI 1.13 - 8.46 [P = 0.028]) and to have superior overall performance scores (aOR 3.29, 95 %CI 1.37 - 7.91 [P = 0.008] and 6.92, 95 %CI 3.77 - 12.69 [P < 0.001], respectively). The benefit of single and multiple EMS practices on overall performance score remained significant after adjustment for success or failure of deep biliary cannulation (aOR 2.98, 95 %CI 1.38 - 6.43 [P = 0.005] and 6.09, 95 %CI 2.40 - 15.45 [P < 0.001], respectively). The benefits of single vs. multiple EMS practices were not statistically different.Coached simulation using EMS improved novice trainees' success of biliary cannulation and overall ERCP performance. Additional uncoached practices did not appear to provide further benefit. Trainees should undergo a coached EMS practice at the beginning of ERCP training.
SAT0081 Patient Involvement in Research is Widely Promoted but Practical Recommendations to Implement IT Are Heterogeneous: A Systematic Literature Review:
Authors: P. Cheung, M. de Wit, L. Gossec
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Patient involvement in medical research has been increasingly promoted by health organisations [1]. However, implementation of this involvement may require specific measures to enhance its efficacy and avoid overburdening patient research partners (PRPs), as advocated in the 2011 EULAR recommendations for the involvement of PRPs in EULAR projects [2], mainly driven by expert opinion due to lack of data at that time. <h3>Objectives</h3> Review currently available literature and guidelines, relating to PRP engagement in the research process. <h3>Methods</h3> A systematic search was performed up to Sept 2013 (Pubmed, Embase, Cochrane and InvoNET). <i>Inclusion criteria:</i> publications of consensus and/or guidelines relating to patient participation/engagement in research, in English. <i>MeSH terms:</i> (Patient research partners/stakeholders/consumer) and (patient participation/community based participatory research/consumer involvement) and (guidelines/recommendations). Explicit recommendations/guidelines for PRP participation in research were focused;lower levels of evidence were also analysed, including descriptive reports of patient involvement in research, and opinion papers. <i>Data:</i> extracted and divided into broad aspects considered important for PRP involvement in research, based on the EULAR recommendations framework and on the authors9 opinion [2]. <h3>Results</h3> We found and screened 550 articles, of these 18 were analysed (2 were unpublished/"gray" literature found on websites). Many papers (n=9, 50%) came from UK; the others from US (N=5), or Europe (N=4). Medical specialties covered, related to chronic diseases, included oncology (N=5), diabetes (N=2), nephrology (N=2) and rheumatology (N=2), while 6 articles were generic in nature. Four articles were actual recommendations (Delphi consensus n=2, literature review, n=2). The other articles were mainly descriptive experiences. The most frequent aspects covered were; extent of patient involvement (78% of articles) and PRP education/training (67% of articles) – Table. <h3>Conclusions</h3> Although PRP involvement is considered important, there are limited explicit recommendations in the literature, of which the EULAR guidelines may be the most practical. The broad concepts covered in the 18 publications were similar indicating some level of consensus. This literature review will form the basis of new formalized guidelines for PRP participation in research useful for both rheumatology and the greater medical community. <h3>References</h3> Boote et al. Health Policy 2006;75:280. de Wit et al. Ann Rheum Dis 2011;70:722. <h3>Acknowledgements</h3> Clifton Bingham, Amye Leong, Lyn March, Pam Monte, Marieke Scholte <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2198
THU0310 Performance of the juvenile arthritis disease activity score JADAS compared to the acr pediatric measures of response in 1470 juvenile idiopathic arthritis patients
Authors: G. Horneff, K. Minden, I. Foeldvari
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The pedACR criteria are validated to analyse the response to a treatment but do not indicate the absolute disease activity nor the absolute improvement. This study correlates the JADAS 71 and 10 to the PedACR 30/50/70. <h3>Methods</h3> Data of the GERMAN BIKER-registry were used to compare the JADAS71 and -10 (Phy. global VAS 0–10cm, Par./pati. global VAS 0–10cm, Active joint count 0-71, Normalized ESR [ESR-20/10]) to the PedACR criteria. <h3>Results</h3> 7960 reports from 1470 JIA pts treated with Etanercept have been analysed. After 3 mths 75% of pts achieved a PedACR30. This number increased to 83% at mth 12 and remained stable thereafter. At mth 3, 45% of pts achieved a PedACR70. This number increased to 62% at mth 12. The median (range) JADAS71 decreased from 18 (0-85) to 4 (0-81) at mth 3, 3 (0-83) at month 6 and 3 (0-57) at month 12, the JADAS10 decreased from 17 (0-40) to 4 (0-35), 3 (0-35), and 3 (0-36). At patient-visits with a PedACR30 the median JADAS10 was 11 (0-29), for PedACR50 6 (0-26), for PedACR70 1 (0-19). In Patient-visit with a failure according to the PedACR the JADAS10 was 12 (0-37). The JADAS71 was 11 (0-49) for PedACR30 responses, 6 (0-47) for PedACR50, 1 (0-25) for PedACR70 response and 12 (0-84) for non-responders (figure). In pts not achieving PedACR30 the JADAS71 and the JADAS10 slightly decreased. In patients achieving a PedACR30/50/70 the JADAS71 decreased by 9.9, 12.3 and 16.7 points, while the JADAS10 decreased by 7.4, 10.0 and 14.9. 1116 (17%) pts achieved the prelim.criteria for inactive disease corresponding to a JADAS-score of 0. <h3>Conclusions</h3> The JADAS allows assessing of absolute disease activity and decreased corresponding to the PedACR. The change from baseline for each of the JADAS measures showed adequate ability to classify each of the PedACR accurately. <h3>Disclosure of Interest</h3> G. Horneff Grant/Research support from: Abbott, Pfizer, K. Minden Grant/Research support from: Pfizer, I. Foeldvari: None Declared
A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy
Authors: R. E. Bellet, H. Ghazal, M. Flam, A. Drelichman, N. Gabrail, D. Woytowitz, D. Loesch, D. Niforos, A. Mangione, L. Anthony
Journal: Journal of Clinical Oncology (2007)

9109 Background: The effect of using IV iron sucrose in managing cancer chemotherapy-related anemia has not been previously reported. To investigate this issue, we conducted a randomized study of IV iron sucrose in patients (pts) with cancer chemotherapy-related anemia who completed 8 prior wks of ESA therapy. Methods: This prospective, multicenter, randomized, open label, Phase III clinical trial enrolled 375 pts with chemotherapy induced anemia (Hgb levels = 10.0 g/dL) and was conducted in 2 stages. During Stage I (8-wk duration), pts received treatment with fixed ESA doses (100-mcg of darbepoetin or 40,000 units epoetin wkly or 200 mcg of darbepoetin every other wk). Pts were classified as either ESA responders (= 1 g/dL increase in Hgb) or ESA non-responders with each group randomized (Stage 2) separately to receive either 12 wks of fixed doses of ESA plus up to 1,500 mg of iron sucrose (given in 3 divided doses of up to 500mg) or 12 wks of fixed doses of ESA alone. Laboratories (including iron indices and acute phase reactants), quality of life and adverse events were assessed at baseline and throughout. Results: Iron sucrose plus ESA compared to ESA alone resulted in greater mean maximum Hgb levels and greater number of pts who achieved Hgb increases = 2.0 and ≥ 3.0 g/dl in both prior ESA responders and non-responders. There was also a statistically significant improvement in fatigue and iron stores in the iron sucrose treated pts. Baseline iron status did not predict responsiveness to iron sucrose therapy. Three serious but non-life threatening iron sucrose related adverse events were observed including one case of significant, transient hypotension in a female weighing 50 kg. Conclusions: IV iron sucrose increased Hgb levels and iron stores significantly and is well tolerated in doses up to 500 mg increments in ESA treated patients with cancer chemotherapy- related anemia. IV iron sucrose should be considered in combination with erythropoietic therapy in anemic cancer patients receiving chemotherapy. [Table: see text]
A MULTICOMPARTMENTAL MODEL FOR IODIDE, THYROXINE, AND TRIIODOTHYRONINE METABOLISM IN NORMAL AND SPONTANEOUSLY HYPERTHYROID CATS.
Authors: Marguerite T. Hays, Michael R. Broome, Jane M. Turrel
Journal: Clinical Nuclear Medicine (1987)

*VA Medical Center, Palo Alto, CA, and Schools of Medicine and Veterinary Medicine, U.C. Davis, Davis, CA.
Blood Volume of Representative Portions of the Musculoskeletal System in Man
Authors: LEO M. KARPELES, REX L. HUFF
Journal: Circulation Research (1955)

A method is described for estimating the quantity of blood in the leg. Experiments evaluating the accuracy and validity of the method using I 131 labeled human serum albumin and in vivo analysis are presented. The data suggest that in the recumbent position the leg is about 5.6 volumes per cent blood. Speculation in regard to the similarity and amount of other portions of the body to the leg lead to the possibility that about six-tenths of the blood is present in the carcass and four-tenths in the viscera.
IMPACT OF SUCCESSFUL REVASCULARIZATION OF CHRONIC TOTAL OCCLUSION ON LONG-TERM CLINICAL OUTCOME
Authors: Tomohiko Teramoto, Etsuo Tsuchikane, Masanori Yamamoto, Seiji Kano, Hitoshi Matsuo, Yoshiaki Kawase, Yoriyasu Suzuki, Kenya Nasu, Maoto Habara, Yoshihisa Kinoshita, Mitsuyasu Terashima, Tetsuo Matsubara, Takahiko Suzuki
Journal: Journal of the American College of Cardiology (2015)
AB0902 Pubescent Status-Related Differential Presentation in Pediatric-Onset Systemic Lupus Erythematosus: an Experience in the Single Center
Authors: K.-S. Shin, J.-S. Kim, E.-J. Park
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Pediatric-onset SLE (pSLE) represents 10-20% of all SLE patients, and several studies suggest that SLE tends to be more severe in pSLE than in adult-onset SLE. However, the impact of age or puberty at disease onset in children remains unclear and has rarely been studied. <h3>Objectives</h3> To evaluate the association between pubescent status and the initial presentation of pSLE. <h3>Methods</h3> Patients with a diagnosis of SLE before the age of 16 years and followed up at Jeju National University Hospital from 2003 to 2013 were eligible for inclusion in this study. Patients were divided into two groups, based on pubertal stage (&gt; Tanner stage II) and/or menarche at diagnosis, defined as pre-pubescent and pubescent. Medical records regarding demographic profile, clinical and laboratory manifestations at diagnosis, SLE Disease Activity Index (SLEDAI) at diagnosis were reviewed. <h3>Results</h3> Forty-two patients with pSLE were included in this study: 36 girls (85.7%) and 6 boys (14.3%). The median age at diagnosis was 12.4 years (range 7.8 to 15.6 years). The cohort of pre-pubescent patients consisted of 9 girls and 5 boys (83.3% in boys), and the most of pubescent patients were girls (27, 96.4% in pubescent). Pre-pubescent patients showed significantly more hematologic and constitutional manifestations at diagnosis compared with pubescent patients, but musculoskeletal, cutaneous, and neurologic involvement occurred more frequently in pubescent patients. Renal involvement, complement level, and autoantibodies at diagnosis were not significantly different between the two cohorts. Pubescent patients showed a significantly higher disease activity score than pre-pubescent patients. <h3>Conclusions</h3> Although the number of patient was so small, these results suggest that the disease activity at diagnosis in pSLE significantly increased after pubescent and the distinct differences in the initial presentation between pre-pubescent and pubescent patients relate to musculoskeletal, cutaneous, and neurologic manifestations. <h3>References</h3> Silverman E, Eddy A. Systemic lupus eythematosus. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors, Textbook of Pediatric Rheumatology. 6th ed. Philadelphia: Elsevier Saunders, 2011; 315-43. Descloux E, Durieu I, Cochat P, Vital-Durand D, Ninet J. Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus. Rheumatol 2009;48:779-84. Hui-Yuen JS, Imundo LF, Avitabile C, Kahn PJ, Eichenfield AH, Levy DM. Early versus later onset childhood-onset systemic lupus erythematosus: Clinical features, treatment and outcome. Lupus 2011;20:952-9. Malattia C, Martini A. Paediatric-onset systemic lupus erythematosus. Best Prac Res Clin Rheumatol 2013;27:351-62. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4172
New Technique Boosts Hopes For Early Lung Cancer Detection
Authors: K. Ruddon
Journal: JNCI Journal of the National Cancer Institute (1988)

New Technique Boosts Hopes For Early Lung Cancer Detection Get access Kate Ruddon Kate Ruddon Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 17, 2 November 1988, Pages 1354–1355, https://doi.org/10.1093/jnci/80.17.1354 Published: 02 November 1988
P2-05-04: Mapping the Specific Gene Families Activated in the Lymphangiogenesis and Vasculogenic Mimicry Exhibited by Inflammatory Breast Cancer.
Authors: H Liu, AZ Luo, Z Mu, K Chu, Z Ye, RK Alpaugh, S Fernandez, KM Boley, J Jin, MC Wright, M Cristofanilli, FM Robertson
Journal: Cancer Research (2011)

Abstract Background: Inflammatory breast cancer (IBC) is the most metastatic variant of locally advanced breast cancer. Although IBC is diagnosed less commonly than other types of breast cancer, it is extremely aggressive, and accounts for a disproportionate number of breast cancer related deaths annually. IBC exhibits very specific patterns of lymphangiogenesis and vasculogenic mimicry, however detailed studies of the genes and proteins involved in these angiogenic processes are lacking. This study performed whole unbiased gene transcription studies with validation by protein arrays using all available pre-clinical cell lines and in vivo xenograft models of IBC, including a new model of IBC, FC-IBC01, which exhibits lymphovascular invasion, to identify the specific pathways involved in the distinctive angiogenesis observed in IBC. Materials and Methods: Real-time quantitative RT-PCR, cDNA microarray gene profiling, immunofluorescence with confocal imaging and protein arrays were used to examine differential expression of specific angiogenic gene families including VEGFA,B,C,D, VEGF Receptor genes, and ANG/TIE genes linked to angiogenesis and lymphangiogenesis. Results: Activity of the matrix metalloproteinase, MMP-2, is required for IBC tumor cells to undergo vasculogenic mimicry (VM), which is associated with a loss of TIMP-2, a well known inhibitor of angiogenesis. Therapeutics that target MMP activity can successfully inhibit this VM. Furthermore, pre-clinical models of IBC that form IBC tumor emboli exhibit lymphovascular invasion that is associated with distinct patterns of expression of genes that encode for distinct receptor tyrosine kinases that may represent important therapeutic targets for IBC. Discussion: Identification of the distinct angiogenic pathways that are activated in IBC provides insight into the therapeutic targets that may abrogate the distinct lymphovascular invasion and vasculogenic mimicry that are linked to the aggressive metastasis of IBC. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-05-04.